Nutex Health (NASDAQ:NUTX) Stock Rating Lowered by Wall Street Zen

Nutex Health (NASDAQ:NUTX) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Nutex Health in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Nutex Health presently has an average rating of “Moderate Buy” and an average price target of $252.50.

Nutex Health Stock Performance

NASDAQ NUTX opened at $90.28 on Friday. The company’s 50 day simple moving average is $136.67 and its two-hundred day simple moving average is $124.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.41 and a quick ratio of 3.39. Nutex Health has a 1 year low of $40.67 and a 1 year high of $193.07. The stock has a market capitalization of $629.25 million, a PE ratio of 10.05 and a beta of 0.04.

Nutex Health (NASDAQ:NUTX) last released its quarterly earnings results on Thursday, March 5th. The company reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95). The firm had revenue of $151.68 million for the quarter, compared to analysts’ expectations of $258.82 million. Nutex Health had a net margin of 7.34% and a return on equity of 17.67%.

Hedge Funds Weigh In On Nutex Health

A number of hedge funds and other institutional investors have recently bought and sold shares of NUTX. Pertento Partners LLP bought a new position in shares of Nutex Health in the 3rd quarter worth $27,940,000. Topline Capital Management LLC lifted its holdings in shares of Nutex Health by 80.0% during the 3rd quarter. Topline Capital Management LLC now owns 556,567 shares of the company’s stock worth $57,505,000 after acquiring an additional 247,436 shares during the last quarter. Marshall Wace LLP grew its position in Nutex Health by 333.4% in the second quarter. Marshall Wace LLP now owns 94,548 shares of the company’s stock worth $11,770,000 after acquiring an additional 72,734 shares in the last quarter. Millennium Management LLC grew its position in Nutex Health by 191.1% in the third quarter. Millennium Management LLC now owns 93,396 shares of the company’s stock worth $9,650,000 after acquiring an additional 61,308 shares in the last quarter. Finally, Divisadero Street Capital Management LP bought a new position in Nutex Health in the second quarter valued at $7,481,000. Hedge funds and other institutional investors own 5.32% of the company’s stock.

More Nutex Health News

Here are the key news stories impacting Nutex Health this week:

• Positive Sentiment: Nutex reported strong full‑year 2025 results (revenue +82% y/y to $875.3M; net income and EPS up; adjusted EBITDA +152.6%) and announced a second stock repurchase program — news that can support the stock over time by reducing share count and signaling management confidence. NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
• Positive Sentiment: Analyst/coverage pieces are discussing valuation upside given earnings growth and the buyback, which may attract long‑term investors focused on fundamentals. Assessing Nutex Health (NUTX) Valuation After Earnings Growth And New Share Buyback Program
• Neutral Sentiment: Corporate press releases and financial filings provide the detailed numbers and management commentary — useful for investors doing due diligence but unlikely to move the market on their own. Company Press Release / Financial Report
• Negative Sentiment: Nutex’s most recent quarterly report missed expectations sharply (EPS $1.61 vs. $5.56 est.; revenue $151.7M vs. $258.8M), a short‑term catalyst for selling as it signals volatility in recent revenue drivers. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple law firms (Block & Leviton, Kuehn Law and others) have launched investigations or encouraged shareholders to contact them over potential securities fraud and fiduciary‑duty claims tied to disclosure of revenue recognition and internal controls — a major overhang that raises litigation risk, potential settlements, and reputational damage. Block & Leviton Investigation Notice
• Negative Sentiment: Additional press items detail similar shareholder litigation allegations about HaloMD-related revenue recognition, internal control weaknesses, and stock‑based compensation treatment — issues that could lead to restatements or future liabilities. Kuehn Law Notice
• Negative Sentiment: Local/regional reporting highlights investor outreach from law firms, amplifying negative headlines and short‑term selling pressure. GazetteXtra: Investor Advisory

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.